NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.

about

Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.

P2860

Q47136441-02AB34D9-C41D-4CCB-8039-447A58DB3662

P2860

NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.

Item

http://www.wikidata.org/entity/Q40519542

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

NPM1, FLT3 and CEBPA mutations ...... ncidence and prognostic value.

@en

type

Item

label

NPM1, FLT3 and CEBPA mutations ...... ncidence and prognostic value.

@en

prefLabel

NPM1, FLT3 and CEBPA mutations ...... ncidence and prognostic value.

@en

P1476

NPM1, FLT3 and CEBPA mutations ...... ncidence and prognostic value.

@en

P2093

A Medina

http://www.w3.org/2001/XMLSchema#string

B Campos

http://www.w3.org/2001/XMLSchema#string

C N Alonso

http://www.w3.org/2001/XMLSchema#string

J A Digiorge

http://www.w3.org/2001/XMLSchema#string

J G Rossi

http://www.w3.org/2001/XMLSchema#string

M S Felice

http://www.w3.org/2001/XMLSchema#string

M S Gallego

http://www.w3.org/2001/XMLSchema#string

Patricia Rubio

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Nonparametric Estimation from Incomplete Observations

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group

P2888

s12185-016-2064-5

P304

582-590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12185-016-2064-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27436336

http://www.w3.org/2001/XMLSchema#string

P921

Argentina

NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.

about

P2860

P2860

NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921